Performance metrics for assessment of clinical trial authorisation (CTA) applications and substantial amendments

We have provided metrics for clinical trials assessment performance, as follows.

- Average timelines for assessment of initial clinical trial authorisation (CTA) applications (by month) for Phase 1 healthy volunteer trials (HVT), initial CTA applications for Phase 1–4 patient trials, and substantial amendments. Since December 2021, applicants have had the flexibility to request additional time to respond to grounds for non-acceptance (GNA); therefore; the average assessment timeline for CTA applications has been divided into 'first review' (from receipt of valid application to first opinion letter) and 'second review' (from receipt of GNA response to final opinion letter). Before December 2021, applicants were required to respond to all GNA within 14 days.
- The number of CTA applications received and assessed by month.
- The number of substantial amendment applications received and assessed by month.
- The number of CTA applications assessed, by month, for the following trial categories: first in human; early phase (Phase 1/2); Phase 1 (healthy volunteers and patients); Phase 2 and 3; and Phase 4.
- The number of CTA applications assessed by sponsor type (non-commercial or commercial).
- The number of CTA applications and substantial amendments assessed, by month, for novel trials designs (eg umbrella, platform, modular, basket).

Figure 1 **Average timeline (calendar days) for assessment of clinical trial applications: initial clinical trial authorisation (CTA) application first review (from receipt of valid application to first opinion issued); initial CTA application second review (time from receipt of GNA response to final opinion); and substantial amendments**



	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Jan-23	Feb-23	Mar-23
Initials Phase 1 HVT, Average of 1st Review	24.55	19.29	26.77	29.23	31.00	29.88	33.33	34.83	38.44	48.17	41.60	61.83
Initials Phase 1 HVT, Average of 2nd Review	12.55	15.00	8.08	11.23	7.42	13.38	13.50	11.58	13.89	15.83	9.60	7.83
Initials Phase 1-4 (Patients), Average of 1st Review	31.54	32.21	30.57	32.70	33.93	35.50	44.78	47.65	52.08	56.59	71.24	86.24
Initials Phase 1-4 (Patients), Average of 2nd Review	18.46	17.68	16.17	12.92	14.87	21.98	19.92	19.24	21.71	25.22	22.46	23.88
Amendments, Average Review	28.00	29.49	30.60	32.03	35.35	36.26	38.39	42.54	46.38	50.08	82.29	52.30

(HVT = Healthy Volunteer Trials)

Figure 1 shows the average time taken for MHRA assessment of clinical trial applications, divided into the following categories: initial clinical trial authorisation (CTA) applications for Phase 1 healthy volunteer trials (HVT); initial CTA applications for Phase 1–4 patient trials; and substantial amendments. Since December 2021, applicants have had the flexibility to request additional time to respond to grounds for non-acceptance (GNA); therefore, the data in Figure 1 are further categorised into: 'first review' – time from receipt of valid CTA application to initial opinion letter; and 'second review' – time from receipt of GNA response to final opinion. The monthly average for each category represents clinical trials for which the final opinion letter was issued in that month (ie outright approval, approval with conditions, or approval of amended request further to a GNA response).

Figure 2 **Number of clinical trial authorisation (CTA) applications ('initials') received and assessed by month (April 2022–March 2023)**



	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Jan-23	Feb-23	Mar-23
Clinical Trial Applications Received	72	84	75	73	80	78	79	68	77	65	82	63
Clinical Trial Applications Assessed	65	78	71	74	66	64	60	51	48	37	30	49

Figure 2 shows the number of valid clinical trial authorisation (CTA) applications received and the number of CTA applications assessed in any given month. The number of applications assessed for any given month is the number of applications for which the first opinion letter was issued in that month (ie first review).

Figure 3 Number of substantial amendments received and assessed by month (April 2022–March 2023)



	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Jan-23	Feb-23	Mar-23
Substantial Amendments Received	498	523	559	610	529	515	476	625	525	373	458	451
Substantial Amendments Assessed	444	437	389	454	370	474	314	304	395	443	346	298

Figure 3 shows the number of substantial amendments received and the assessed in any given month. The number of amendments assessed for any given month is the number for which an opinion letter was issued in that month.

Figure 4 Number of first-in-human CTA applications assessed by month (April 2022–March 2023)



	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Jan-23	Feb-23	Mar-23
Number of FIH studies	9	4	14	7	9	4	7	20	14	7	12	12

(CTA = Clinical trial authorisation; FIH= First in Human)

Figure 4 shows the number of first-in-human clinical trial authorisation (CTA) applications assessed by month. The number of applications assessed for any given month is the number of applications for which the first opinion letter was issued in that month (ie first review).

Figure 5 Number of early phase CTA applications assessed by month (April 2022–March 2023)



	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Jan-23	Feb-23	Mar-23
Early Phase Trials	20	17	29	24	27	18	20	28	18	10	21	26

Figure 5 shows the number of clinical trial authorisation (CTA) applications assessed, by month, where the Sponsor has declared a Phase 1 element (e.g. Phase 1/2 trials). The number of applications assessed for any given month is the number of applications for which the first opinion letter was issued in that month (ie first review).

Figure 6 Number of phase 1 CTA applications assessed by month (April 2022–March 2023)



	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Jan-23	Feb-23	Mar-23
Phase 1 Patients	12	3	7	10	9	8	6	8	6	3	8	9
Phase 1 Healthy Volunteers	6	11	11	10	9	7	8	14	5	6	8	12

Figure 6 shows the number of Phase 1 clinical trial authorisation (CTA) applications assessed by month. The number of applications assessed for any given month is the number of applications for which the first opinion letter was issued in that month (ie first review).

Figure 7 Number of phase 2 and 3 CTA applications assessed by month (April 2022–March 2023)



	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Jan-23	Feb-23	Mar-23
Phase 2 & 3 Trials	42	59	38	40	36	40	36	21	29	26	9	22

Figure 7 shows the number of clinical trial authorisation (CTA) applications assessed, by month, where the Sponsor has declared a Phase 2 or 3 element. The number of applications assessed for any given month is the number of applications for which the first opinion letter was issued in that month (ie first review).

Figure 8 Number of phase 4 CTA applications assessed by month (April 2022–March 2023)



	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Jan-23	Feb-23	Mar-23
Phase 4 Trials	3	2	4	9	3	6	4	2	1	1	0	1

Figure 8 shows the number of clinical trial authorisation (CTA) applications assessed, by month, where the Sponsor has declared the trial to be Phase 4. The number of applications assessed for any given month is the number of applications for which the first opinion letter was issued in that month (ie first review).

Figure 9 Number of clinical trial authorisation (CTA) applications ('initials') assessed by sponsor type by month (April 2022–March 2023)



	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Jan-23	Feb-23	Mar-23
Non-Commercial	13	11	9	13	6	11	10	5	5	2	6	9
Commercial	52	67	62	61	60	53	50	46	43	35	24	40

Figure 9 shows the number of clinical trial authorisation (CTA) applications assessed in any given month, spit by commercial and non-commercial sponsors. The number of applications assessed for any given month is the number of applications for which the first opinion letter was issued in that month (ie first review).

Figure 10 Number of novel trial designs assessed by month: initial clinical trial authorisation (CTA) applications and amendments (April 2022–March 2023)



	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Jan-23	Feb-23	Mar-23
Amendments	2	0	3	1	2	0	0	1	2	3	0	0
Initials	1	2	1	2	1	2	3	2	0	1	1	0

Figure 10 shows the number of clinical trial authorisation (CTA) applications ('initials') and the number of substantial amendments assessed for novel trial designs (eg umbrella, platform, modular, basket) by month. The data for initials assessed in any given month represent the number of CTA applications for which the first opinion letter was issued in that month. Figure 10 does not show the number of applications received.